Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00828841 |
|
Recruitment Status :
Completed
First Posted : January 26, 2009
Results First Posted : October 11, 2013
Last Update Posted : November 6, 2013
|
Sponsor:
Accelerated Community Oncology Research Network
Information provided by (Responsible Party):
Accelerated Community Oncology Research Network
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-Small Cell Lung Cancer | Drug: Cetuximab Drug: Paclitaxel Drug: Carboplatin Drug: Gemcitabine Drug: Cisplatin | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 601 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Study Start Date : | December 2008 |
| Actual Primary Completion Date : | July 2012 |
| Actual Study Completion Date : | August 2012 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Lung cancer
Drug Information available for:
Cetuximab
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Paclitaxel, Carboplatin, Cetuximab (Arm A)
Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
|
Drug: Cetuximab
Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
Other Name: Erbitux Drug: Paclitaxel Paclitaxel 200 mg/m2 Day 1 every 21 days
Other Name: Taxol Drug: Carboplatin Carboplatin AUC 6 Day 1 every 21 days
Other Name: Paraplatin |
|
Active Comparator: Platinum, Gemcitabine, Cetuximab (Arm B)
Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
|
Drug: Cetuximab
Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
Other Name: Erbitux Drug: Carboplatin Carboplatin AUC 6 Day 1 every 21 days
Other Name: Paraplatin Drug: Gemcitabine Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
Other Name: Gemzar Drug: Cisplatin Cisplatin 75 mg/m2 Day I every 21 days
Other Name: Platinol |
|
Active Comparator: Platinum, Pemetrexed, Cetuximab (Arm C)
Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
|
Drug: Cetuximab
Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
Other Name: Erbitux Drug: Carboplatin Carboplatin AUC 6 Day 1 every 21 days
Other Name: Paraplatin Drug: Cisplatin Cisplatin 75 mg/m2 Day I every 21 days
Other Name: Platinol |
Primary Outcome Measures :
- Overall Survival by Treatment Arm [ Time Frame: Survival was measured from the date of randomization to date of death due to any cause, assessed up to 36 months. Subjects who were alive at the date of last contact were censored at the date of last contact. ]
Secondary Outcome Measures :
- 1-year Survival by Treatment Arm [ Time Frame: Survival was measured from the date of randomization to date of death due to any cause, assessed up to 36 months. Subjects who were alive at the date of last contact were censored at the date of last contact. ]
- Overall Survival by Histology [ Time Frame: Survival was measured from the date of randomization to date of death due to any cause, assessed up to 36 months. Subjects who were alive at the date of last contact were censored at the date of last contact. ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent before study-related activities
- Histologically or cytologically confirmed Stage IIIb with cytologically documented malignant pleural or pericardial effusion, Stage IV, or recurrent non-smal cell lung cancer (NSCLC) after resection or radiation for earlier stage disease
- Measurable or evaluable disease (per modified Response Evaluation Criteria in Solid Tumors [RECIST] guidelines)
- Male or female ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- White blood count ≥ 3 x 10(9)/L with neutrophils ≥ 1.5 x 10(9)/L, platelet count ≥ 100 x 10(9)/L, and hemoglobin ≥ 9.5 g/dL
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver mets
- Serum creatinine ≤ 1.25 x ULN
- Recovery from prior surgery or radiation to Grade 1 or better toxicity
- Women of childbearing potential (WOCBP) and fertile men with partners of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 wks after the study in such a manner that the risk of pregnancy is minimized
- WOCBP must have a negative serum or urine pregnancy test within 72 hrs prior to the start of study medication or in accordance with local regulations, whichever is of shorter duration
Exclusion Criteria:
- WOCBP who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 4 weeks after the study
- Women who are pregnant or breastfeeding
- Women with a positive pregnancy test during screening or prior to study drug administration
- Sexually active fertile men not using effective birth control if their partners are women of child-bearing potential
- Prior chemo for advanced NSCLC; neoadjuvant or post-operative adjuvant chemo is allowed if completed at least 12 months before study entry
- Previous exposure to epidermal growth factor receptor (EGFR)-targeted therapy. Prior treatment with monoclonal antibodies targeting receptors other than the EGFR, such as bevacizumab, is allowed if completed > 30 days prior to randomization
- Treatment with any investigational agent(s) within 4 weeks prior to study entry
- Concurrent anti-cancer therapy (chemotherapy, hormonal therapy, biologic or targeted therapy) other than protocol therapy
- Carcinoid, atypical carcinoid or small cell lung cancer
- Symptomatic or uncontrolled mets in the central nervous system
- Prior invasive malignancy requiring ongoing therapy within the past year
- Active infection (infection requiring intravenous [IV] antibiotics), including active tuberculosis, known and declared HIV
- Myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current Grade 3 or 4 cardiovascular disorder despite treatment
- Known allergic/hypersensitivity reaction to any of the components of study treatments
- Peripheral neuropathy ≥ Grade 2, as assessed by Common Terminology Criteria for Adverse Events, version 3.0
- History of significant neurologic or psychiatric disorders including but not limited to dementia, seizures, and bipolar disorder
- Medical or psychological condition that would not permit the patient to complete the study or sign informed consent
- Known drug abuse
Patients of all races and ethnic groups are eligible for this trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00828841
Locations
Show 84 study locations
Sponsors and Collaborators
Accelerated Community Oncology Research Network
Investigators
| Study Chair: | Lee Schwartzberg, MD, FACP | Accelerated Community Oncology Research Network |
| Responsible Party: | Accelerated Community Oncology Research Network |
| ClinicalTrials.gov Identifier: | NCT00828841 |
| Other Study ID Numbers: |
AC01L08 |
| First Posted: | January 26, 2009 Key Record Dates |
| Results First Posted: | October 11, 2013 |
| Last Update Posted: | November 6, 2013 |
| Last Verified: | October 2013 |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Gemcitabine Paclitaxel Carboplatin Cetuximab Antineoplastic Agents, Phytogenic |
Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Immunological |